Dose-Response Effects of Insulin Glargine in Type 2 Diabetes by Wang, Zhihui et al.
Dose-Response Effects of Insulin Glargine
in Type 2 Diabetes
ZHIHUI WANG, MD
1
MAKA S. HEDRINGTON, MD
2
NINO GOGITIDZE JOY, MD
2
VANESSA J. BRISCOE, PHD, NP
1
M. ANTOINETTE RICHARDSON, RN
2
LISA YOUNK, BS
2
WENDELL NICHOLSON, BS
1
DONNA B. TATE, MS
2
STEPHEN N. DAVIS, MBBS
1,2
OBJECTIVE — To determine the pharmacokinetic and pharmacodynamic dose-response
effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes.
RESEARCHDESIGNANDMETHODS — Twentyobesetype2diabeticindividuals(10
male and 10 female, aged 50  3 years, with BMI 36  2 kg/m
2 and A1C 8.3  0.6%) were
studied in this single-center, placebo-controlled, randomized, double-blind study. Five subcu-
taneousdosesofinsulinglargine(0,0.5,1.0,1.5,and2.0units/kg)wereinvestigatedonseparate
occasions using the 24-h euglycemic clamp technique.
RESULTS — Glargine duration of action to reduce glucose, nonessential fatty acid (NEFA),
and -hydroxybutyrate levels was close to or 24 h for all four doses. Increases in glucose ﬂux
revealed no discernible peak and were modest with maximal glucose infusion rates of 9.4, 6.6,
5.5, and 2.8 mol/kg/min for the 2.0, 1.5, 1.0, and 0.5 units/kg doses, respectively. Glargine
exhibited a relatively hepatospeciﬁc action with greater suppression (P  0.05) of endogenous
glucose production (EGP) compared with little or no increases in glucose disposal.
CONCLUSION — Asinglesubcutaneousinjectionofglargineatadoseof0.5units/kgcan
acutely reduce glucose, NEFA, and ketone body levels for 24 h in obese insulin-resistant type 2
diabeticindividuals.GlarginelowersbloodglucosebymainlyinhibitingEGPwithlimitedeffects
onstimulatingglucosedisposal.Largedosesofglarginehaveminimaleffectsonglucoseﬂuxand
retain a relatively hepatospeciﬁc action in type 2 diabetes.
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T
ype 2 diabetes is a condition of rel-
ative or absolute insulin deﬁciency.
Consequently, insulin replacement
becomes a common and essential therapy
in these individuals. Insulin therapy in
type 2 diabetes can range from a single
injection to basal-bolus replacement reg-
imenswith multipledailyinjections.In-
sulin glargine is a soluble long-acting
insulin analog that is widely used in
clinical practice for basal insulin re-
placement.
Numerous studies have investigated
the clinical efﬁcacy of insulin glargine in
both type 1 and type 2 diabetes (1–3).
Glargine has been found to lower A1C,
provide effective basal insulin replace-
ment, and reduce the risk of hypoglyce-
mia (1–3). Despite the widespread use of
glargine in clinical practice, there have
been relatively few studies investigating
the pharmacokinetic and pharmacody-
namic characteristics of the insulin. Two
studies have investigated subcutaneous
doses of 0.3 and 0.35 U glargine in type 1
diabetic individuals (4,5). Other studies
also using a 24-h glucose clamp tech-
nique have compared the pharmacoki-
netics and pharmacodynamics of single
doses of glargine (0.5 and 0.8 units/kg) in
patients with type 2 diabetes (6,7). These
studies provide valuable information
about single doses of glargine in patients
with diabetes. Klein et al. (8) have also
compared three doses of glargine (0.4,
0.8, and 1.4 units/kg) in type 2 diabetes
during 24-h clamp studies using the
Biostator. However, because the Biosta-
tor has been reported to limit maximal
glucose infusions during a glucose
clampandalsoproduceawidevariation
of blood glucose concentrations around
the target glucose value (9), we rea-
soned that further information regard-
ing the dose-response characteristics of
insulin glargine in patients with type 2
diabetes would also be useful. The aim
of the present study was to use the 24-h
euglycemic clamp technique to deter-
mine the pharmacokinetics and phar-
macodynamics of differing large, single
subcutaneous doses of glargine (similar
to those used in clinical practice in
treatment of obese insulin-resistant
type 2 diabetic individuals). Isotope di-
lution methods were used to determine
the effects of glargine on endogenous
glucose production and glucose dis-
appearance.
RESEARCH DESIGN AND
METHODS— This single-center, ran-
domized, double-blind, ﬁve-period study
was approved by the Vanderbilt Univer-
sity Institutional Review Board. Twenty
individuals (10 male and 10 female, aged
50  3 years, with diabetes duration 8 
1 years, BMI 36  2 kg/m
2, and A1C
8.3  0.6%) were studied. None had ma-
jor complications of diabetes, all were
nonsmokers, and all had normal renal
and hematological function. Some indi-
viduals had mild elevations of hepatic
transaminases suggestive of nonalcoholic
steatohepatosis that were 1.5 times the
upper normal limit. All study subjects
were receiving various combination ther-
apy for glucose control. All study subjects
were receiving metformin, and this was
combinedwithsulfonylureas(6patients),
exenatide (6 patients), insulin (either
glargine, detemir, Humalog, or NovoLog,
70–30 mixtures; 14 patients). Insulin
doses ranged from 11 to 70 units/day
(supplementary Table 1, available in
an online appendix at http://care.
diabetesjournals.org/cgi/content/full/
dc09-2011/DC1).
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clamps
The study consisted of ﬁve separate ex-
periments, each lasting 26 h and sepa-
rated by 6–8 weeks. In each
experiment, individuals received sub-
cutaneously into the abdomen either
0.5, 1.0, 1.5, or 2.0 units/kg glargine or
an identical placebo injection (0 units/
kg)inarandomized,double-blindfash-
ion. Each limb of the study consisted of
12 individuals.
Exenatide was withheld for 24 h, and
oral medications and long- and interme-
diate-acting insulins were withheld for
60 h before each study. Individuals con-
tinued their normal weight-maintaining
diet and participated in no exercise for 3
days before each experiment. Glucose
control was maintained if necessary with
short-acting insulin on the day before
each study. Individuals were admitted to
the Vanderbilt General Clinical Research
Center at 5:00 P.M. before an experi-
ment. A hand vein was cannulated in a
retrograde fashion and maintained in a
heated box (55°C) so that arterialized
bloodcouldbesampled(10).Inaddition,
aveininthecontralateralarmwascannu-
lated so that insulin, 20% dextrose, and
glucose tracer could be administered. An
intravenous insulin infusion was started
to control glucose during a standardized
evening meal and a 9:00 P.M. snack and
was constantly adjusted overnight to
maintainplasmaglucosebetween5.0and
6.0 mmol/l. After a 9-h overnight fast, a
primed (10 Ci in 10 min) continuous
infusion (0.092 Ci/min) of [
3H-
3]glucose was started at time 120 min
and continued throughout the experi-
ment. Plasma glucose was maintained at
euglycemia during the 120-min isotope
equilibration period by continuing the
overnight insulin infusion. At time 0 min,
a dose of glargine was administered sub-
cutaneously into the abdominal area. The
overnight insulin infusion was discontin-
ued 45 min after the glargine injection.
During the clamp period, plasma glucose
concentrations were measured every
15–30 min, and a 20% dextrose infusion
was used, when necessary, at a variable
rate to maintain the plasma glucose con-
centration at the target value of 5.5
mmol/l (11). Blood for experimental pa-
rameters was sampled every 30 min–2 h
throughout the study. The glucose clamp
study was ended 24 h after subcutaneous
injection of glargine.
Tracer calculations
Rates of glucose appearance, endogenous
glucose production (EGP), and glucose
utilization were calculated according to
the method of Wall et al. (12). EGP was
calculated as the total glucose production
minus the exogenous glucose infusion
rate. Total glucose production comprises
EGP and any exogenous glucose that was
infused to maintain the desired euglyce-
mia.Tomaintainaconstantspeciﬁcactiv-
ity (and reduce underestimates of glucose
kinetics), isotope delivery was increased
commensurate with increases in exoge-
nous glucose infusion.
Calculations
Pharmacodynamic parameters of insulin
action were calculated as follows: 1) end
of action, time at which plasma glucose
was consistently (for at least 60 min)
7.0 mmol/l (126 mg/dl), and 2) maxi-
mum glucose infusion rate (g/kg/min).
Analytical methods
Plasma glucose concentrations were mea-
sured in triplicate using the glucose oxi-
dase method with a glucose analyzer
(Beckman, Fullerton, CA). Subcutane-
ously administered insulin glargine
(A21-Gly-B31-Arg-B32-Arg-insulin) pre-
cipitatesattheinjectionsitefromwhichit
is gradually liberated into the blood-
stream in three equivalently bioactive
forms, insulin glargine, A21-Gly-insulin,
and A21-Gly-des-B30-Thr-insulin, plus
A21-Gly-B31-Arg-insulin, a minor me-
tabolite of unknown biological potency
(13). The virtually complete sequence
homology among insulin glargine, its
metabolites, and insulin facilitates im-
munoassay of the former compounds
withmethodsdevelopedfortheassayof
human insulin (14,15). However, these
assays can only measure total immunore-
active insulin in human plasma. Conse-
quently,thecontributionofinsulinglargine
and its metabolites to total plasma insulin
cannot be calculated unless each glargine
component is known to react equally in
the immunoassay and endogenous insu-
lin can be discounted. An insulin radio-
immunoassay (PI-12K; Millipore, St.
Charles, MO) that uses recombinant hu-
man insulin as reference was used in the
present study. The sensitivity of the assay
is 0.05 ng (1.25 -I.U.)/ml, and the inter-
assay coefﬁcients of variation (CV) at 0.8
ng(20IU),2.28ng(57IU),and6.0ng
(150 IU)/ml are 3, 7, and 9%,
respectively.
C-peptide was determined using a ra-
dioimmunoassay kit (HCP-20HK; Milli-
pore). The sensitivity of the assay is 0.1
ng/mlandtheCVsat0.34and1.41ng/ml
are 8.5 and 5%, respectively.
Plasma glucagon concentrations were
measured using a modiﬁcation of the
method of Aguilar-Parada et al. (16) with
an interassay CV of 12%. Plasma nones-
teriﬁed fatty acid (NEFA) concentra-
tionsweredeterminedusingtheWAKO
kit. Plasma -hydroxybutyrate was mea-
sured using the method of Lloyd et al. (17).
Statistical analysis
Results are expressed as means  SE and
were analyzed for statistical comparisons
using one- and two-way ANOVA. P 
0.05 was accepted as a signiﬁcant differ-
encebetweendoses.Calculationsandsta-
tistical analyses were performed using
SPSS (version 16.0; SPSS, Chicago, IL).
Group differences were tested by a least
signiﬁcant difference multiple compari-
son test. The linear trapezoidal rule was
used to calculate the AUC for plasma glu-
cose, glucose infusion rate, and plasma
insulin.
RESULTS
Plasma glucose levels
After placebo injection, plasma glucose
levels increased to 8.7  0.3 mmol/l at
24 h (Fig. 1). After 0.5 units/kg glargine,
plasma glucose was maintained at 6.1
mmol/luntil18handthenincreasedpro-
gressively (P  0.05) to a peak of 7.2 
0.7 mmol/l at 24 h. In contrast, with
higher doses of glargine (1.0, 1.5, and 2.0
units/kg), plasma glucose levels were
maintained at 5.7  0.3, 5.6  0.2, and
5.3  0.1 mmol/l at 24 h, which were
signiﬁcantly reduced (P  0.05) com-
pared with those for placebo.
Insulin, C-peptide, glucagon levels
The ﬁnal 2 h of intravenous insulin ad-
ministration were similar in each group
(2.1  0.6, 1.9  0.3, 1.9  0.6, 2.1 
0.2,and2.30.5units/hforplaceboand
0.5, 1.0, 1.5, and 2.0 units/kg, respec-
tively). During the placebo (time control
no exogenously administered insulin
studies), basal insulin levels fell slowly
andcontinuouslyovera24-hperiodfrom
132  18 to 94  4 pmol/l (Fig. 1). After
glargine administration, insulin levels
were signiﬁcantly increased (P  0.05)
compared with those for placebo (Fig. 1)
and followed a physiological pattern (i.e.,
smooth slow decrease over 24 h) similar
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glargine produced stepwise increases
(P  0.05) in mean insulin levels only up
to 1.0 units/kg (137  23, 216  14,
254  25, and 259  27 pmol/l for 0.5,
1.0, 1.5, and 2.0 units/kg, respectively).
No glargine dose produced a discernible
peak in insulin concentration. Interindi-
vidual CVs for insulin levels were 45, 51,
54, and 46% for the 0.5, 1.0, 1.5, and 2.0
units/kg glargine doses, respectively.
There were no differences in average
plasma insulin levels between the 1.0,
1.5, and 2.0 units/kg doses.
Glargine administration signiﬁcantly
inhibited (P  0.05) the release of C-
peptide compared with placebo (Fig. 1).
Incremental AUC C-peptide levels were
signiﬁcantly lower during the 1.0, 1.5,
and 2.0 units/kg doses than during the
0.5 units/kg dose (P  0.05). There were
no differences in incremental AUC C-
peptide values after 1.0, 1.5, and 2.0
units/kg doses. Plasma glucagon levels
were signiﬁcantly reduced (P  0.05)
compared with those for placebo by all
glargine doses (supplementary Fig. 1,
available in an online appendix).
Glucose kinetics
Glucose infusion was not required after
placebo. The incremental AUCs for the
glucoseinfusionratetomaintaineuglyce-
mia were 64  23, 149  46, 213  70,
and 247  60 mol/kg for 0.5, 1.0, 1.5,
and 2.0 units/kg, respectively. All were
signiﬁcantly increased (P  0.05) com-
pared with those for placebo, and the in-
cremental AUCs during the 1.0, 1.5, and
2.0 units/kg doses were increased (P 
0.05) compared with that for the 0.5
units/kg dose. The peak glucose infusion
rates were 2.8  0.9, 5.5  1.5, 6.6 
2.0, and 9.4  2.0 mol/kg/min in the
0.5, 1.0, 1.5, and 2.0 units/kg doses, re-
spectively. All peak glucose infusion rates
were signiﬁcantly increased (P  0.05)
after glargine administration compared
with those for placebo. Peak infusion
rates were also higher (P  0.05) in the
1.0, 1.5, and 2.0 units/kg doses than in
the 0.5 units/kg dose. Glucose infusion
rates at the end of the 24-h study for the
four glargine doses in increasing order
were 0.2  0.17, 1.8  1.0, 3.0  1.6,
and3.71.1mol/kg/min,respectively.
Endogenous glucose production was
suppressed during the placebo time con-
trol (Fig. 2). Glargine at 0.5 units/kg pro-
duced suppression of EGP similar to that
for placebo. Glargine doses of 1.0, 1.5,
and 2.0 units/kg produced greater sup-
pression (P  0.05) of EGP than placebo.
Glucose rates of disappearance were not
signiﬁcantly increased by any of the
glargine doses compared with those for
placebo (Fig. 2). Endogenous glucose
productionwassuppressedbyarelatively
greater amount (P  0.05) during pla-
cebo and all glargine doses compared
with the respective changes in glucose
disappearance (Table 1).
Intermediary metabolism
Plasma NEFA levels were suppressed
(P  0.05) in a stepwise fashion with in-
creasing doses of glargine. Blood -hy-
droxybutyrate followed a similar pattern
withasigniﬁcantlygreaterreduction(P
0.05) of the ketone body with increasing
doses of glargine (supplementary Fig. 1).
CONCLUSIONS — In this study, we
examined the pharmacokinetic and phar-
macodynamic dose-response effects of
single subcutaneous injections of insulin
Figure 1—Effects of single injections of insulin glargine (0, 0.5, 1.0, 1.5, and 2.0 units/kg) on
plasma glucose. Insulin and C-peptide levels in overnight fasted type 2 diabetic individuals.
Plasmaglucoselevelsat24haresigniﬁcantlyincreased(P0.05)intheplaceboand0.5units/kg
dose groups. Plasma insulin levels are signiﬁcantly increased (P  0.05) compared with that for
placebo after all doses of glargine; 1.0, 1.5, and 2.0 units/kg doses of glargine are increased (P 
0.05) compared with the 0.5 units/kg dose. Plasma C-peptide levels are signiﬁcantly decreased (P
 0.05) compared with that for placebo. Incremental AUC values after 1.0, 1.5, and 2.0 units/kg
doses are also signiﬁcantly lower (P  0.05) than after the 0.5 units/kg dose.
Wang and Associates
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uals. Our study demonstrates that over a
dose range of 0.5 to 2.0 units/kg, glargine
lowers plasma glucose by a relatively
hepatospeciﬁcmechanism.Inobeseinsu-
lin-resistant type 2 diabetic individuals,
alloftheglarginedosesexertedmetabolic
effects throughout the 24-h clamp study.
Circulating plasma insulin levels in-
creased modestly despite large subcuta-
neous glargine doses (200 U). Peak
insulin levels plateaued after the 1.5 and
2.0 units/kg doses at 259  27 pmol/l,
which was barely double the insulin val-
ues after the 0.5 units/kg dose. The glu-
cose infusion rates needed to maintain
euglycemia were also modest with peak
values of 9 mol/kg/min required after
the largest 2.0 units/kg dose.
Plasma glucose was maintained at or
7.0 mmol/l for 2 3ha f t e rt h e0 . 5
units/kg dose and for 24 h with the 1.0,
1.5, and 2.0 units/kg doses. In addition,
NEFA, -hydroxybutyrate, and C-
peptide levels were all suppressed, rela-
tive to those for placebo for 24 h. This
indicates that in this present group of
obese, insulin-resistant type 2 patients
single subcutaneous glargine doses of
0.5 units/kg can have a time action pro-
ﬁle close to or longer than 24 h. Because
in this present study, we investigated the
effects of a single subcutaneous dose of
glargine, we cannot determine whether
repeated doses of glargine at 0.5 units/kg
given over a longer period would also
have resulted in a longer duration of
action. This is a possibility, because Por-
cellati et al. (18) have demonstrated ex-
tended duration of action of glargine at a
dose of 0.3 units/kg after 1 week of re-
peated daily use in a group of type 1 dia-
betic individuals. Luzio et al. (19) have
also used the 24-h euglycemic clamp
technique to investigate 0.5 units/kg of
glargine in type 2 diabetic individuals
(19). In their study, glargine at 0.5
units/kg had a 24-h duration of action.
However, the type 2 diabetic individuals
investigated by Luzio et al. were very dif-
ferent from the present study cohort be-
cause they were less obese, had better
glycemic control, and were all treated
with oral hypoglycemic agents. Thus, the
subjects would have been predicted to be
less insulin resistant and also seemed to
have less advanced type 2 diabetes. Sup-
portingthisassumptionistheﬁndingthat
the maximal glucose infusion rate in the
studyofLuzioetal.was9pmol/kg/min,
which was equivalent to the largest glu-
cose infusion rate occurring in this study
after a 4-fold higher dose of glargine (2.0
units/kg).
Because glargine can have a variable
activation time (18), we decided, a priori,
to maintain the overnight infusion of in-
sulin for 45 min in all studies. This is the
reason that there was a small increase in
plasma glucose levels after glargine ad-
Figure 2—Effects of single injections of insulin glargine (0.0.5, 1.0, 1.5, and 2.0 units/kg) on
endogenous glucose production, glucose rate of disappearance, and glucose infusion rates in
overnight fasted type 2 diabetic individuals. Rates of endogenous glucose production are signiﬁ-
cantly suppressed by a greater amount (P  0.05) after 1.0, 1.5, and 2.0 units/kg compared with
that for placebo. Rates of glucose disposal are similar after placebo and all doses of glargine.
Glucose infusion rates are signiﬁcantly increased (P  0.05) after all doses of glargine compared
with that for placebo. Incremental AUC values for 1.0, 1.5, and 2.0 units/kg doses were also
signiﬁcantly increased compared with that for 0.5 units/kg dose.
Dose-response glargine
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ies. In addition, because the initial period
of the clamps would have reﬂected both
subcutaneous glargine and intravenous
insulin administration, we did not report
plasma insulin levels until 2 h into the
clamp studies. The insulin proﬁles from
each of the injected doses did not display
any demonstrable peak. In addition, the
elevations in circulating plasma insulin
weredramaticallytruncatedandwerenot
proportional to the linear increases of the
subcutaneously injected insulin glargine.
Thus,insulinlevelswereonly30pmol/l
(5U/ml)higherthanthoseforplacebo
after the 0.5 units/kg dose. Insulin levels
increased 80 pmol/l (14 U/ml) be-
tween the 0.5 and 1.0 units/kg doses.
Thereafter,therewasonlyameannonsig-
niﬁcant 38 pmol/l (6 units/ml) in-
crease between the 1.0 to 1.5 units/kg
doses and no difference in insulin levels
betweenthe1.5and2.0units/kgdoses.In
fact,themeanmaximalinsulinlevelsafter
the1.5and2.0units/kgdoseswereequiv-
alentatonly312–318pmol/l(52–53U/
ml). It is also worth noting that, based on
work by Ciaraldi et al. (20), this level of
glargine has binding similar to that of
skeletalmuscleIGF-Ireceptorscompared
with equivalent levels of human insulin.
This result provides reassurance that
glargine levels at even very high clinical
doses do not have increased mitogenic
potential. When the insulin levels are in-
terpreted, some additional points may
warrantconsideration.Thecirculatingin-
sulinlevelsrepresentacombinationofex-
ogenous and endogenous insulin. The
endogenous C-peptide area under the
curvewassuppressedbyagreateramount
for the 24-h study after the largest doses
of glargine compared with that for pla-
cebo or the 0.5 units/kg dose. Thus, it
may be assumed that the suppressed en-
dogenousinsulinlevelsmayhavecontrib-
utedarelativelyloweramounttothetotal
plasma insulin level during the higher
dose glargine clamp studies. In addition,
measurement of insulin levels after sub-
cutaneous glargine administration is
complicated by circulating metabolites of
the molecule that have both differential
metabolic effects and abilities to cross-
react in a conventional insulin immuno-
assay.Thus,theplasmainsulinlevelsafter
glargine may represent an overestimate of
the total circulating glargine species
present in the plasma (13). Nevertheless,
what is evident from this study is that the
chemical formulation of the glargine mol-
eculedramaticallylimitsabsorptionofin-
sulin from the subcutaneous tissue and
acts as a buffer to limit circulating insulin
levels(19,21).Webelievethattheformu-
lation of insulin glargine is a major deter-
minant of the pharmacokinetic proﬁle of
themoleculeastheinterindividualCVsof
insulin levels in the present study ranged
from 45 to 54% and are similar to values
reported previously with nonanalog ex-
tended-action insulins (22).
Glargineloweredplasmaglucosebya
relatively hepatospeciﬁc mechanism. At
each dose level, endogenous glucose pro-
duction was suppressed by a greater
amount compared with any relative in-
creaseinglucosedisposal.Infact,noneof
the glargine doses increased glucose dis-
posal by a signiﬁcantly greater amount
than placebo. Contributing to the rela-
tively hepatospeciﬁc action was the effect
of glargine on glucagon and NEFA levels.
Glucagon is known to be a signiﬁcant
contributor to basal EGP (23). Thus, the
effects of glargine to suppress glucagon
duringtheglucoseclampscouldalsohave
been a contributory mechanism for the
relative hepatospeciﬁc action. In addi-
tion, the effects of glargine to reduce cir-
culating NEFA levels would also have
effects to lower EGP. The reduced -hy-
droxybutyratelevelsafterglargineadmin-
istrationalsosupportthehepaticactionof
themolecules.ConversionofNEFAtoke-
tonebodieslargelyoccursintheliver,and
this was signiﬁcantly reduced during the
present studies. During fasting, EGP falls
as glycogen stores are used (22). Further-
more, physiologically endogenous basal
insulin has a relatively hepatospeciﬁc ef-
fect. This can be clearly seen in the pla-
cebo experiments. However, what the
present studies have demonstrated is that
insulin glargine doses up to 2.0 units/kg
(withinjectedinsulindoses200U)also
lower fasting glucose in type 2 diabetes in
a “physiological” hepatospeciﬁc manner.
Although the doses of glargine used
in type 1 diabetes practice are usually
quite low (0.5 units/kg), the amount of
glargineusedinmanagingtype2diabetes
isoftenconsiderablyhigher.Therefore,in
this present study, we have studied the
acute24-hpharmacokineticandpharma-
codynamic effects of large doses of
glargine (0.5–2.0 units/kg) in type 2 dia-
betes. We should point out that the study
was performed in the southeastern U.S.
where there is a very high prevalence of
type 2 diabetes and accompanying obe-
sity. Our study population had a mean
B M Io f3 6 2 kg/m
2 and was clearly
obese. Additional studies investigating
the pharmacokinetic and pharmacody-
namic dose-response characteristics of
glargine using lower doses of the insulin
in less obese individuals would also be
useful. In addition, we should also men-
tion that in this study, glargine was ad-
ministered in the morning, which occurs
in clinical practice but not as commonly
as evening dosage. Furthermore, the
pharmacodynamicsofglarginemaybein-
ﬂuenced by the time of administration.
Thedawnphenomenonwithitsattendant
changes in plasma glucose and insulin
sensitivity can occur 4–8 h after evening
dosage but 20 h after a morning injec-
tion. Thus, the pattern of glucose kinetics
might have been altered if glargine had
been administered in the evening.
In summary, in this study we have
investigated the pharmacokinetics and
pharmacodynamics of large doses (0.5–
2.0 units/kg) of insulin glargine in obese
type 2 diabetic individuals. A single sub-
Table 1—Pharmacodynamic effects of subcutaneous injections of glargine in type 2 diabetes
0 units/kg 0.5 units/kg 1.0 units/kg 1.5 units/kg 2.0 units/kg
Plasma glucose at end of study (mmol/l) 8.7  0.8 7.2  0.7* 5.7  0.3*† 5.6  0.2*† 5.3  0.1*†
Maximum glucose infusion rate (mol/kg/min) 0.3  0.3 2.6  0.9* 5.5  1.5*† 6.8  2.0*† 9.5  2.1*†
Glucose infusion rate at end of study (mol/kg/min) 0.0  0.0 0.2  0.2 1.87  1.0* 3.0  1.6*† 3.7  1.1*†
Suppression of EGP (%) 28  4‡ 45  6*‡ 71  10*‡ 61  12*‡ 80  15*‡
Increase in glucose disposal rate (%) 2.3  4.0 4.0  3.8 10  71 2  10 24  18
Data are means  SE. *P  0.05 compared with 0 units/kg (placebo). †P  0.05 compared with 0.5 units/kg glargine. ‡P  0.05 compared with increase in glucose
disposal rate.
Wang and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1559cutaneous injection of glargine can have a
duration of action of at least 24 h. Very
large doses result in modest increases in
glucose ﬂux with no discernible peak ac-
tion. This seems to be due to the limited,
peakless, and continuous release of the
insulin from the subcutaneous tissue.
Glargine lowers plasma glucose by a pre-
dominantlyhepatospeciﬁcaction(i.e.,in-
hibiting endogenous glucose production)
with minimal effects on stimulation of
glucose disposal.
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